Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.36 |
| ▸ | KIT | P10721 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22050653 | 0.81 | JAK2 (0.47) | CYP2C9CYP2C19KITCYP3A4AAK1 | |
| SCHEMBL24565966 | 0.80 | KIT (0.48) | CYP2C9CYP2C19KITCYP3A4AAK1 | |
| SCHEMBL13199611 | 0.76 | LRRK2 (0.51) | AAK1 | |
| SCHEMBL27920535 | 0.74 | SLC22A6 (0.45) | CYP2C9CYP2C19KITCYP3A4AAK1 | |
| SCHEMBL7921128 | 0.72 | MET (0.46) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL25839066 | 0.72 | KIT (0.41) | CYP2C9CYP2C19KITCYP3A4AAK1 | |
| SCHEMBL22049684 | 0.70 | TDO2 (0.39) | DYRK1A | |
| SCHEMBL1045946 | 0.69 | BRD4 (0.54) | CYP2C9CYP2C19KITCYP3A4DYRK1A | |
| SCHEMBL21902710 | 0.69 | CYP2C19 (0.40) | CYP2C9CYP2C19CYP3A4DYRK1A | |
| SCHEMBL15154998 | 0.69 | GSK3B (0.56) | CYP2C9CYP2C19KITCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CYP2C9 4838/4885CYP2C19 4839/4885KIT 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.